search
Back to results

Safety Study on AdCD40L Gene Therapy for Bladder Cancer

Primary Purpose

Bladder Cancer

Status
Completed
Phase
Phase 1
Locations
Sweden
Study Type
Interventional
Intervention
AdCD40L
Sponsored by
Uppsala University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bladder Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically proven diagnosis of transitional cell carcinoma of the bladder
  • ECOG 0-2
  • 18 years of age or older
  • signed informed consent
  • for the Phase I part: patient scheduled for cystectomy

Exclusion Criteria:

  • Woman of childbearing potential (fertile woman)
  • Other malignancy within 5 years of study, except for non-melanoma skin cancer
  • Metastatic disease
  • Previous exposure to any intravesical therapy for bladder cancer: within 3 months for chemotherapy and within 6 months for BCG therapy.
  • Previous pelvic radiation or treatment with any cytotoxic, immunologic or chemotherapeutic agent for non-malignant conditions within 5 years of study.
  • Clinically abnormal hepatic, renal or bone marrow function, or coagulation disorders in the opinion of the investigator.
  • Chronic urinary tract infections.
  • Serous infection of G.U. surgery, except for bladder cancer, within 1 month of study requiring more than 3 days of hospital care.
  • Vesical capacity <150mL and/or vesical obstruction with residual >150 mL after spontaneous voiding.
  • Previous exposure to any experimental drug within 3 months from enrolment.
  • Any significant medical or psychiatric illness that would prevent the patient from giving informed consent of from following the study procedures.
  • Patients who presently have urothelial cell carcinoma of the upper G.U. tract
  • Patients with systemic autoimmune disease
  • Patients that do not consent to that tissue and blood samples are stored in a biobank
  • Treatment with systemically administered corticosteroids and NSAID within 4 weeks prior to first study treatment

Sites / Locations

  • Uppsala University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AdCD40L

Arm Description

Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.

Outcomes

Primary Outcome Measures

Toxicity

Secondary Outcome Measures

Inflammation

Full Information

First Posted
April 30, 2009
Last Updated
January 15, 2010
Sponsor
Uppsala University
Collaborators
Uppsala University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00891748
Brief Title
Safety Study on AdCD40L Gene Therapy for Bladder Cancer
Official Title
A Phase I/IIa Study of Dose-escalating Intravesical AdCD40L Instillation in Urinary Bladder Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
April 2009
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
October 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Uppsala University
Collaborators
Uppsala University Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study objective is to evaluate the feasibility of three instillations of immunostimulating gene therapy (AdCD40L) in patients with urinary bladder cancer. Tolerance, toxicity and immunological parameters will be evaluated during and post treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AdCD40L
Arm Type
Experimental
Arm Description
Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
Intervention Type
Genetic
Intervention Name(s)
AdCD40L
Intervention Description
Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
Primary Outcome Measure Information:
Title
Toxicity
Time Frame
Continously during therapy and at follow up 30d
Secondary Outcome Measure Information:
Title
Inflammation
Time Frame
Continously during treatment and at follow up 30d

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically proven diagnosis of transitional cell carcinoma of the bladder ECOG 0-2 18 years of age or older signed informed consent for the Phase I part: patient scheduled for cystectomy Exclusion Criteria: Woman of childbearing potential (fertile woman) Other malignancy within 5 years of study, except for non-melanoma skin cancer Metastatic disease Previous exposure to any intravesical therapy for bladder cancer: within 3 months for chemotherapy and within 6 months for BCG therapy. Previous pelvic radiation or treatment with any cytotoxic, immunologic or chemotherapeutic agent for non-malignant conditions within 5 years of study. Clinically abnormal hepatic, renal or bone marrow function, or coagulation disorders in the opinion of the investigator. Chronic urinary tract infections. Serous infection of G.U. surgery, except for bladder cancer, within 1 month of study requiring more than 3 days of hospital care. Vesical capacity <150mL and/or vesical obstruction with residual >150 mL after spontaneous voiding. Previous exposure to any experimental drug within 3 months from enrolment. Any significant medical or psychiatric illness that would prevent the patient from giving informed consent of from following the study procedures. Patients who presently have urothelial cell carcinoma of the upper G.U. tract Patients with systemic autoimmune disease Patients that do not consent to that tissue and blood samples are stored in a biobank Treatment with systemically administered corticosteroids and NSAID within 4 weeks prior to first study treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per-Uno Malmstrom, MD PhD
Organizational Affiliation
Uppsala University Hospital, Uppsala, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Uppsala University Hospital
City
Uppsala
ZIP/Postal Code
75185
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Safety Study on AdCD40L Gene Therapy for Bladder Cancer

We'll reach out to this number within 24 hrs